Triglav Skladi D.O.O. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Key Points

• Triglav Skladi D.O.O. increased its stake in Johnson & Johnson by 5.0%, owning 62,500 shares worth approximately $10.37 million as of its latest SEC filing.
• Major institutional investors have also evaluated their positions in Johnson & Johnson, with Brighton Jones LLC increasing its stake by 13.9% and CreativeOne Wealth LLC boosting its holdings by 69.1% in the last quarter.
• Johnson & Johnson recently declared a quarterly dividend of $1.30, representing a 3.0% yield, with the payout scheduled for September 9.

Triglav Skladi D.O.O. grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,500 shares of the company's stock after buying an additional 3,000 shares during the period. Johnson & Johnson makes up about 0.9% of Triglav Skladi D.O.O.'s holdings, making the stock its 29th biggest holding. Triglav Skladi D.O.O.'s holdings in Johnson & Johnson were worth $10,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. Cohen & Steers Inc. raised its holdings in Johnson & Johnson by 5.3% during the 4th quarter. Cohen & Steers Inc. now owns 2,472 shares of the company's stock valued at $358,000 after buying an additional 125 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in Johnson & Johnson by 69.1% during the 4th quarter. CreativeOne Wealth LLC now owns 28,241 shares of the company's stock valued at $4,084,000 after buying an additional 11,541 shares during the last quarter. Finally, Lafayette Investments Inc. raised its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Lafayette Investments Inc. now owns 48,960 shares of the company's stock worth $7,081,000 after purchasing an additional 597 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on JNJ. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $172.79 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $174.76. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $416.14 billion, a PE ratio of 18.48, a P/E/G ratio of 2.21 and a beta of 0.41. The company has a 50-day simple moving average of $160.00 and a two-hundred day simple moving average of $157.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 EPS. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.